StockData

Acadia Pharmaceuticals vs Pacira BioSciences

ACAD and PCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACAD and PCRX compare

Acadia Pharmaceuticals is the larger company, worth 2.2 times as much as Pacira BioSciences ($3.2B against $1.5B).

On earnings, Acadia Pharmaceuticals is cheaper: it trades at 8.3× trailing earnings, against 104× for Pacira BioSciences.

Acadia Pharmaceuticals grew revenue faster over the last twelve months (11.8% versus 5.7% for Pacira BioSciences).

Acadia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with 2.0% at Pacira BioSciences.

Acadia Pharmaceuticals scores higher on the StockData Score (16 against 6 for Pacira BioSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACADPCRX
Size and price
Market cap$3.2B$1.5B
Share price$18.32$36.48
Change, 1 year−23.7%53.4%
Change, 5 years−2.5%−29.3%
Beta (5Y)0.530.12
Employees798829
StockData Score
Total score16 (better)6
Valuation score4 (better)0
Growth score2 (better)1
Performance score4 (better)3
Health score6 (better)2
Dividend score00
Valuation
P/E8.3× (better)104×
P/S2.8×1.9× (better)
P/B2.4×2.2× (better)
EV/EBITDA25.5×14.9× (better)
P/FCF21.7×8.1× (better)
FCF yield4.6%12.3% (better)
Fair value$25.26$28.47
Margin of safety27.5% (better)−28.1%
Growth
Revenue growth (TTM)11.8% (better)5.7%
Revenue growth, 5Y average19.4% (better)11.1%
Net income growth (TTM)71.3%–
EPS growth (TTM)66.2%–
EPS growth, 5Y average–−45.5%
Profitability
Gross margin91.1% (better)79.2%
Operating margin7.6% (better)2.7%
Net margin33.4% (better)2.0%
FCF margin12.8%24.1% (better)
Return on equity35.7% (better)2.0%
Return on invested capital42.1% (better)3.0%
Financial health
Debt / equity0.000.54 (better)
Net debt / EBITDA–1.07
Interest coverage–1.3×
Current ratio3.395.04 (better)
Altman Z-score4.32 (better)2.44
Piotroski F-score68 (better)
Dividends and buybacks
Buyback yield−1.5%10.2% (better)
Shareholder yield−1.5%10.2% (better)
Ownership
Held by institutions97.9%110%
Held by insiders27.8%6.1%
Insider net buying, 12 months−$2.5M−$2.4M (better)
Short interest, % of float6.7%8.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.